Advertisement

Human Cell

, Volume 33, Issue 1, pp 261–271 | Cite as

MiR-490-5p functions as tumor suppressor in childhood neuroblastoma by targeting MYEOV

  • Jinfeng Wang
  • Xin ZhangEmail author
  • Hongyue Yao
  • Yuan Le
  • Wei Zhou
  • Jing Li
  • Lingling Lu
  • Meixue Chen
  • Xiang Li
Research Article
  • 21 Downloads

Abstract

Neuroblastoma (NB) is the most common extracranial solid tumor derived from neural crest in children. Recently, the role of miRNA has been studied extensively in the development of NB. Here, we investigated the clinical significance of microRNA-490-5p (miR-490-5p) in NB. A total of 72 pairs of NB tumor tissues and matched adjacent normal nerve tissues were collected from NB patients. The expression of miR-490-5p was significantly down-regulated in NB tissues and cell lines using quantitative real-time PCR. Using Pearson Chi-square test and Kaplan–Meier analysis, we found that significantly decreased miR-490-5p levels were correlated with INSS stage, lymph-node metastasis, and poor survival prognosis in NB patients. MiR-490-5p overexpression significantly suppressed cell proliferation migration, invasion, and induced cell cycle G0/G1 arrest and cell apoptosis in NB cell lines (SH-SY5Y and SK-N-SH) using CCK-8, flow cytometry, and transwell assays. Mechanistically, MYEOV was confirmed as a target gene of miR-490-5p by luciferase reporter assay. Furthermore, MYEOV knockdown imitated, while overexpression rescued the changes in the biological features of miR-490-5p on NB cells. Our results demonstrated for the first time that miR-490-5p functions as a tumor suppressor in NB by targeting MYEOV, which might provide novel approaches for the treatment of NB.

Keywords

Neuroblastoma miR-490-5p MYEOV Prognosis Tumor suppressor 

Notes

Funding

Not applicable.

Compliance with ethical standards

Conflict of interest

The authors have declared no conflict of interest.

Ethics approval and consent to participate

All the protocols in this study were approved by the Ethics Committee of Jinzhou Medical University First Affiliated Hospital (Approval number: FM2314-124).

Consent for publication

Not applicable.

References

  1. 1.
    Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin N Am. 2010;24:65–86.CrossRefGoogle Scholar
  2. 2.
    Wang Z, Yao W, Li K, et al. Reduction of miR-21 induces SK-N-SH cell apoptosis and inhibits proliferation via PTEN/PDCD4. Oncol Lett. 2017;13:4727–33.CrossRefGoogle Scholar
  3. 3.
    Ahmed AA, Zhang L, Reddivalla N, Hetherington M. Neuroblastoma in children: update on clinicopathologic and genetic prognostic factors. Pediatr Hematol Oncol. 2017;34:165–85.CrossRefGoogle Scholar
  4. 4.
    Ma J, Xu M, Yin M, et al. Exosomal hsa-miR199a-3p promotes proliferation and migration in neuroblastoma. Front Oncol. 2019;9:459.CrossRefGoogle Scholar
  5. 5.
    Park JR, Bagatell R, London WB, et al. Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013;60:985–93.CrossRefGoogle Scholar
  6. 6.
    Garaventa A, Parodi S, De Bernardi B, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 2009;45:2835–42.CrossRefGoogle Scholar
  7. 7.
    Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122:6–7.CrossRefGoogle Scholar
  8. 8.
    Berindan-Neagoe I, Monroig Pdel C, Pasculli B, Calin GA. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014;64:311–36.CrossRefGoogle Scholar
  9. 9.
    Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8.CrossRefGoogle Scholar
  10. 10.
    Cheng X, Xu Q, Zhang Y, et al. miR-34a inhibits progression of neuroblastoma by targeting autophagy-related gene 5. Eur J Pharmacol. 2019;850:53–63.CrossRefGoogle Scholar
  11. 11.
    Xu Y, Chen X, Lin L, Chen H, Yu S, Li D. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification. Biochimie. 2017;139:1–8.CrossRefGoogle Scholar
  12. 12.
    Murray MJ, Raby KL, Saini HK, et al. Solid tumors of childhood display specific serum microRNA profiles. Cancer Epidemiol Biomarkers Prevent. 2015;24:350–60.CrossRefGoogle Scholar
  13. 13.
    Janssen JWG, Imoto I, Inoue J, et al. MYEOV, a gene at 11q13, is coamplified withCCND1, but epigenetically inactivated in a subset of esophageal squamous cell carcinomas. J Hum Genet. 2002;47:460–4.CrossRefGoogle Scholar
  14. 14.
    Janssen JW, Vaandrager JW, Heuser T, et al. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood. 2000;95:2691–8.PubMedGoogle Scholar
  15. 15.
    Specht K, Haralambieva E, Bink K, et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood. 2004;104:1120–6.CrossRefGoogle Scholar
  16. 16.
    Moss AC, Lawlor G, Murray D, et al. ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion. Biochem Biophys Res Commun. 2006;345:216–21.CrossRefGoogle Scholar
  17. 17.
    Lawlor G, Doran PP. MYEOV (myeloma overexpressed gene) drives colon cancer cell migration and is regulated by PGE2. J Exp Clin Cancer Res CR. 2010;29:1–5.CrossRefGoogle Scholar
  18. 18.
    Fang L, Wu S, Zhu X, et al. MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF-β pathway in NSCLC. Oncogene. 2019;38(6):896.CrossRefGoogle Scholar
  19. 19.
    Takita J, Chen Y, Okubo J, et al. Aberrations of NEGR1 on 1p31 and MYEOV on 11q13 in neuroblastoma. Cancer Sci. 2011;102:1645–50.CrossRefGoogle Scholar
  20. 20.
    Lan G, Yang L, Xie X, Peng L, Wang Y. MicroRNA-490-5p is a novel tumor suppressor targeting c-FOS in human bladder cancer. AMS. 2015;11:561–9.PubMedGoogle Scholar
  21. 21.
    Chen K, Zeng J, Tang K, et al. miR-490-5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA. Biol Cell. 2016;108:41–50.CrossRefGoogle Scholar
  22. 22.
    Li S, Xu X, Xu X, et al. MicroRNA-490-5p inhibits proliferation of bladder cancer by targeting c-Fos. Biochem Biophys Res Commun. 2013;441:976–81.CrossRefGoogle Scholar
  23. 23.
    Yang L, Ma J, Tan Y, et al. Cardiac-specific overexpression of metallothionein attenuates L-NAME-induced myocardial contractile anomalies and apoptosis. J Cell Mol Med. 2019;7:4640–52.Google Scholar
  24. 24.
    Yamamichi F, Shigemura K, Behnsawy HM, et al. Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer. Scand J Urol. 2014;48:523–32.CrossRefGoogle Scholar
  25. 25.
    Chen W, Ye L, Wen D, Chen F. MiR-490-5p inhibits hepatocellular carcinoma cell proliferation, migration and invasion by directly regulating ROBO1. Pathol Oncol Rese POR. 2019;25:1–9.CrossRefGoogle Scholar
  26. 26.
    Xu B, Xu T, Liu H, Min Q, Wang S, Song Q. MiR-490-5p suppresses cell proliferation and invasion by targeting BUB1 in hepatocellular carcinoma cells. Pharmacology. 2017;100:269–82.CrossRefGoogle Scholar
  27. 27.
    Kai H, Kitadai Y, Kodama M, et al. Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res. 2005;25:709–13.PubMedGoogle Scholar
  28. 28.
    Janssen JWG, Cuny M, Orsetti B, et al. MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer. Int J Cancer. 2002;102:608.CrossRefGoogle Scholar

Copyright information

© Japan Human Cell Society and Springer Japan KK, part of Springer Nature 2020

Authors and Affiliations

  • Jinfeng Wang
    • 1
  • Xin Zhang
    • 2
    Email author
  • Hongyue Yao
    • 1
  • Yuan Le
    • 1
  • Wei Zhou
    • 1
  • Jing Li
    • 1
  • Lingling Lu
    • 1
  • Meixue Chen
    • 1
  • Xiang Li
    • 1
  1. 1.Department of PediatricsJinzhou Medical University First Affiliated HospitalJinzhouChina
  2. 2.Department of OncologyJinzhou Medical University First Affiliated HospitalJinzhouChina

Personalised recommendations